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ABSTRACT
A matrix dispersion type transdermal drug delivery system of domperidone 
was developed using different ratios of rosin with Eudragit RL and Eudragit 
RS. The effect of the polymers on the technological properties, i.e., drug release, 
water vapor transmission rate, percentage moisture loss and thickness were 
investigated. The patch containing Eudragit RL: Eudragit RS (8:2) showed a 
release of 87.10% in 12 h. Formulation D1 emerged as the most satisfactory 
formulation as far as the technological properties were concerned. Further skin 
permeation and skin irritation studies were carried out on rat skin and rabbit 
respectively.  Therefore it can be concluded that the patch containing Eudragit 
RL: Eudragit RS in the ratio 8:2 achieved the desired objectives of transdermal 
drug delivery systems, such as overcoming of first pass effect, extended release 
and reduced frequency of administration.
KEY WORDS: Domperidone hydrochloride. Eudragit RL. Eudragit RS. Release 
studies. Transdermal patch.
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RESUMEN
Se ha desarrollado un sistema de administración de fármaco transdérmico de 
matriz de dispersión de domperidona utilizando diferentes coeficientes de resina 
con Eudragit RL y Eudragit RS. Se ha investigado el efecto de los polímeros en 
las propiedades tecnológicas, es decir, liberación del fármaco, coeficiente de la 
transmisión del vapor del agua, porcentaje de pérdida de humedad y espesor. 
El parche con Eudragit RL: Eudragit RS (8:2) ha mostrado una liberación 
de 87,10% en 12 h. La formulación D1 ha resultado ser la formulación más 
satisfactoria, en la medida que afecta a las propiedades tecnológicas. Se han 
llevado a cabo otros estudios sobre permeabilidad e irritación cutánea en piel 
de ratones y de conejos respectivamente. Por lo tanto, se puede determinar que 
el parche que contiene RL: Eudragit RS en un coeficiente de 8:2 ha alcanzado 
los objetivos fijados de los sistemas de administración de fármaco transdérmico 
como una superación del efecto del primer pase, liberación prolongada y 
frecuencia reducida de administración.
PALABRAS CLAVE:  Clorhidrato domperidona, Eudragit RL, Eudragit RS, estudio de 
liberación, parche transdérmico.
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INTRODUCCIÓN
Drug delivery through the skin to achieve a systemic effect 
of a drug is commonly known as transdermal drug delivery. 
In order to deliver therapeutic agents through the human 
skin for systemic effects, the comprehensive morphological, 
biophysical and physicochemical properties of the skin are 
to be considered1. Compared with oral and parental routes, 
drug delivery through skin can offer several advantages 
for example bypassing the hepatic “first pass” elimination2, 
maintaining a constant, prolonged and therapeutically 
effective drug level in the blood stream or tissues3, 
rapid termination of drug delivery4, improved patient 
compliance5. However, transdermal delivery is limited to 
drugs having low doses, low melting points and molecular 
weights and a solubility of greater than 1 mg/ml in both 
water and mineral oil6. The disadvantage of this design is 
that it needs 6 to 8 h for a therapeutical plasma level to 
appear after application.
In the transdermal delivery systems, polymeric membrane 
is a key component and used to modulate the release rate 
of a therapeutic drug.  A plasticizer is supposed to weaken 
the intermolecular forces between the polymer chains, 
resulting in a softened and flexible polymer matrix.  Thus 
drug permeability through the membranes may also be 
affected by the addition of a plasticizer7.  
Domperidone Hydrochloride is a drug used to treat 
gastrointestinal disorders; it is contraindicated for 
individuals with hypersensitivity, gastrointestinal 
obstruction, perforation, or hemorrhage and prolactinoma. 
Caution should be used in patients with hepatic disease 
and with those taking anticholinergics, since they may 
antagonize the effect of domperidone in the gastrointestinal 
(GI) tract.  The literature reveals that Domperidone 
Hydrochloride undergoes variable and extensive first pass 
metabolism before entering into systemic circulation. 
MATERIALS AND METHODS
Materials
Eudragit RL and Eudragit RS were procured from Rohm 
Pharma, West Germany; Domperidone HCl was obtained 
as gift sample from Micro Labs, Hosur, India; Diethyl 
phthalate form Microfine chemicals, Mumbai, India, 
Chloroform from Qualigens Fine chemicals,  Mumbai, 
India; Ethyl alcohol from Changshu Yangyuan Chemical, 
China and N,N Dimethyl formamide and Mercury were 
from Merck, India Ltd., Mumbai, India. Membrane for 
the permeability studies was the dorsal section of full 
thickness skin from Wistar rats weighing around 200 – 
250 g, whose hair had been previously removed with an 
electronic clipper.  Stratum corneum was prepared from 
the full thickness skin.
Methods
Preparation of film
Polymer matrix solution preparation
The composition of various film formulations is given in 
Table 1. The compositions were devised using polymers 
along with the drug. Chloroform, Ethanol and Dimethyl 
formamide were used as solvents for the film and the 
polymers were weighed accurately and dissolved in 
corresponding solvents. To this polymer solution 10.0% 
w/w plasticizer was added and mixed well. Calculated 
amount of the drug was added to the polymer solution 
and mixed using a cyclomixer; the uniform dispersion 
was poured on the mercury surface and dried at room 
temperature for 24 h. Controlled solvent evaporation was 
achieved by placing an inverted funnel over the petri dish. 
The dry films were removed and kept in a desiccator until 
used.  
Drug compatibility studies
Excipients are integral components of almost all 
pharmaceutical dosage forms. The stability of a formulation 
amongst other factors depends on the compatibility of the 
drug with the excipients, thus it is mandatory to detect any 
possible physical or chemical interaction as it can affect the 
bioavailability and stability of the drug. The drug and the 
excipients must be compatible with one another to produce 
a product that is stable, efficacious, attractive and easy to 
administer and safe. FT-IR and X-ray diffraction studies 
were used to investigate any physicochemical interactions 
between drug and excipients used in the formulation. 
Physicochemical properties of the films
The films were evaluated for the following physicochemical 
properties.
Film thickness
The thickness of the patches was determined using screw 
Tabla 1. Composition of patches.
Ingredients in mg D1 D2 D3
Domperidone 20 20 20
Eudragit RL 200 150 125
Eudragit RS 50 100 125
Diethyl phthalate (%w/w) 
of the polymer 10 10 10
Chloroform 1.5 1.5 1.5
Ethanol 0.5 0.5 0.5
Dimethylformamide 0.5 0.5 0.5
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gauge, recording a mean of three determinations. 
Weight Variation
Four films from each batch were weighed individually and 
the average weight was calculated. 
Drug content
Films of a specified area were cut and weighed accurately. 
Pieces were taken into a 100 ml volumetric flask and 50 
ml of phosphate buffer solution (pH 7.4) was added and 
stirred vigorously for 4 hr to extract drug.   Finally the 
solution was suitably diluted with pH 7.4 buffer, and 
samples were analyzed spectrophotometrically at 205 nm 
for drug content.
Moisture content
The prepared patches were cut into 20 X 50 mm strips, 
were weighed individually and kept in a desiccator 
containing calcium chloride at 37°C for 24 h. The films 
were reweighed individually until a constant weight 
was obtained. Percentage of moisture content was then 
calculated based on the change in the weight with respect 
to the initial weight of the film.
Moisture absorption studies
The water absorption capacities of various films were 
determined at 75% relative humidity (RH). Films were cut 
into 20 X 50 mm strips, were weighed, kept in a desiccator 
at 40°C for 24 h, removed and exposed to RH conditions 
of 75% (containing saturated solution of sodium chloride) 
in different desiccators at room temperature. Weight was 
taken periodically until a constant weight was obtained. 
The water absorption capacity of the films (in weight 
%) was calculated in terms of percentage increase in the 
weight of film over the initial weight of the strip.
Flatness and elongation brake
Longitudinal strips were cut from the prepared medicated 
films. The flatness was determined at various points by 
using vernier calipers.  The percentage elongation brake 
was determined by noting the length just before the break 
point and determined.
Folding endurance
Folding endurance was determined by repeatedly folding 
the film at the same place until it broke.  The number of 
times the film could be folded at the same place without 
breaking was the folding endurance.
Scanning electron microscopy
In order to know general morphology and drug releasing 
pores of the formulation SEM was taken using a Philips XL 
30 scanning electron microscope at an excitation voltage 
of 20 kV.
In vitro Permeation Studies
An in vitro permeation study was carried out by using 
diffusion cell. Full thickness abdominal skin of male 
Wistar rats weighing 150 to170g was used. Hair from 
the abdominal region was carefully removed by using a 
electric clipper; the dermal side of the skin was thoroughly 
cleaned with distilled water to remove any adhering 
tissues or blood vessels, equilibrated for an hour in pH 7.4 
buffer before starting the experiment and was placed on a 
magnetic stirrer with a small magnetic needle for uniform 
distribution of the diffusant. The temperature of the cell was 
maintained at 37 ± 0.5°C using a thermostatically controlled 
heater. The isolated rat skin piece was mounted between 
the compartments of the diffusion cell, with the epidermis 
facing upward into the donor compartment.  Sample volume 
of 1 ml was removed from the receptor compartment at 
regular intervals and an equal volume of fresh medium 
was added. Samples were filtered through Whatman filter 
paper No: 41 and analyzed spectrophotometrically at 205 
nm.  The study was performed for twenty four hours, and 
amount of drug release was calculated.
Skin irritation and sensitization testing 
Skin irritation and sensitization testing were performed 
on healthy rat (average weight: 150 to 170 g). The dorsal 
surface (25cm2) of the rat was cleaned, and the hair was 
removed by shaving after the skin was cleaned using 
rectified spirit and the representative formulations were 
applied over the skin. These were removed after 24 h and 
the skin was examined for any untoward reaction. 
Stability studies
Stability testing has become an integral part of formulation 
development. It generates information on which proposal 
for shelf life of drug or dosage form along with their 
recommended storage conditions are provided as per ICH 
guidelines for stability study for new drug development. 
The formulation was stored at 25oC and 65% RH for 12 
months for long term stability study. The samples were 
taken and analyzed for their physicochemical parameters 
at the end of 3rd month.
RESULTS AND DISCUSSION
Three different compositions of patches containing varying 
proportions of Eudragit RL and Eudragit RS were prepared. 
The composition is shown in Table 1. 
Plasticizer is often incorporated in transdermal therapeutic 
system to give flexibility to the polymer matrix, thereby 
improving their contact with the skin; plasticizers lower 
the temperature of the second order phase transition of 
Formulation and Evaluation of Matrix Diffusion Controlled Transdermal Patches of Domperidone hydrochloride
34 Ars Pharm. 2011; 52(1): 31-36.
the polymer and increase the workability, flexibility and 
permeability of the drug, in the present study, 10% w/w 
was added to the polymer solution.  
FTIR and X-ray diffraction studies were performed to 
investigate chemical interactions between drug and 
the excipients. Domperidone Hydrochloride shows 
characteristic absorption at 3442.80 (NH stretch), 2830.32 
(methyl frequencies), 1619.61 (NH bonds), 1698 (aromatic 
combination bonds) and 706.13 (aliphatic chloro compound) 
these characteristic bands were present in all spectra, no 
new bands or shift in characteristic peaks appeared.  IR 
spectra are shown in Fig 1. XRD of Domperidone shows at 
15.2, 22.9, 23.8 and 44.3 degrees these characteristic peaks 
were present in XRD, no new peaks or shift in characteristic 
peaks appeared. XRD are shown in Fig 2.  From FTIR and 
XRD results reveal that there is no interaction between the 
drug and the excipients used in the formulation.
The formulated films were characterized for various 
parameters such as thickness, uniformity of weight, flatness 
and elongation brake (%), folding endurance, moisture 
content, moisture absorption and drug content.  These 
are essential parameters for the evaluation of the dosage 
form in order to achieve a formulation with uniformity and 
consistency within a batch. The results are shown in Table 
2. The drug content analysis of the prepared formulations 
show that the processes used to prepare the patches in this 
investigation gives uniform drug content, minimum batch 
variability and exhibit uniform thickness and uniformity 
of weight. The uniformity in drug content, uniformity of 
weight and thickness indicates that the polymeric solution 
of the drug is well dispersed. However little variations 
were observed in different formulations, which may be 
due to the variation in polymeric content.
Release studies are required to predict the reproducibility 
of rate and duration of drug release. The importance of 
polymer dissolution on drug release from matrices is 
essential for ensuring sustained release performance. 
Drug release from a transdermal therapeutic system can 
be characterized in terms of the rate and extent to which 
the drug is released from the device by in vitro diffusion 
studies.  The in vitro diffusion studies are predictive 
of in vivo performance of a drug. Release of drug from 
transdermal patches is controlled by the chemical properties 
of drug, form of delivery as well as the physiological and 
physicochemical properties of the biological membrane 
(Rao et al. 2000). Rate controlling factors include, drug 
concentration in the matrix, chemical nature of matrix 
material and device geometry. The cumulative amount of 
Domperidone hydrochloride permeated through the rat 
abdominal skin, into a receptor solution, as a function of 
time. The mean cumulative amounts of drug permeated 
from the formulations were found to be 87.10%, 67.13% 
and 54.25% for D1, D2 and D3 respectively after 12 h; the 
results are shown in Fig 3.  From the results it reveals that 
formulation D1 showed the better release when compared 
to others. The drug release data obtained for formulation 
Tabla 1. FT-IR spectra of drug, excipients and physical mixture.
RL-100: Eudragit RL-100
RS-100:  Eudragit RS-100
DOM: Domperidone hydro-
chloride
DOM-FORM: Domperidone 
hydrochloride formulation 
%T
cm-1
4000                     3000                   2000                   1500                   1000                            400
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Figure 3. In-vitro release profile of formulations D1 to D3
Tabla 1. X-RD pattern of pure drug, excipients and physical mixture .
DOM: Domperidone hydrochloride
RL-100: Eudragit RL-100
RS-100: Eudragit RS-100
DOM-FORM: Domperidone 
hydrochloride formulation
Tabla 2. Physical characteristics of Domperidone patches.
Physical characteristics D1 D2 D3
Thickness 0.16±0.014 0.14±0.014 0.15±0.014
Uniformity of weight (g) 0.265 ±0.013 0.249 ±0.001 0.264±0.001
Flatness and elongation brake (%) 99.6 ±1.26 102.0 ±1.26 96.0 ±1.67
Folding endurance (no’s) 124.0 ±1.67 119.0 ±2.19 127.0 ±1.54
Moisture content (%) 4.49 ±0.017 3. 95±0.018 4.04 ±0.023
Moisture absorption (%) 2.45 ±0.009 1.27 ±0.008 2.94 ±0.009
Drug content (mg) 19.37 ±0.93 19.02 ±0.74 18.03 ±0.75
D1 was plotted according to Zero order, first order, 
Higuchi, Korsemeyer-Peppas equation and Hixson Crowell 
equation. The above results were verified with respect 
to the linear regression coefficient (r2) and the results are 
shown in Table 3.  From the above kinetic studies, it was 
observed and inferred that the release of the drug from the 
formulation D1 follows the first order release kinetic and 
Higuchi diffusion equation. Hixon Crowell equation also 
found to be linear, these indicates that the release from the 
patch was both diffusion and erosion method. 
Results of SEM analysis, performed to investigate the 
surface morphologies and pore size of before and after 
diffusion of patches and the SEM photographs are shown 
in Fig 4 and 5.  The results of skin irritation studies show 
no signs of erythema when compared to that of the control; 
the absence of edema indicates that the polymeric patches 
are compatible with the skin.
Stability testing of the prepared formulation was carried out 
at 25oC and 65% RH for 3 months. The samples were taken 
and analyzed for their physicochemical parameters for 3 
months. The physicochemical parameters like appearance, 
thickness, unformity of weight, moisture content, moisture 
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Figure 4. SEM photographs of domperidone 
transdermal patch before diffusion
absoption and drug content were found to be satisfacotry, 
and there is no change with respected to the initial analysis 
results. 
CONCLUSION
 The present study shows that Domperidone 
Hydrochloride patch containing Eudragit RL and Eudragit 
RS in the ratio 4:1 with 10%w/v of diethyl phthalate 
achieved the desired objectives of transdermal drug 
delivery systems, such as overcoming of first pass effect, 
extended release and reduced frequency of administration 
may serve as a better system for transdermal delivery.  It 
also satisfies the requirements of modern drug delivery 
systems in delivering the drug in predetermined manner.    
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